Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Allergic diseases are highly prevalent worldwide and affect all age groups, contributing to a high personal and socioeconomic burden. Treatment with an “allergy vaccine” or allergen immunotherapy (AIT) aims to provide long-lasting benefits by inducing unresponsiveness to the relevant antigen. The consequences of the therapy are considered disease modifying and range from dampening of the immediate immune responses to the reduction of secondary tissue remodeling. Furthermore, AIT interventions have a potential to slow or cease the development of additional allergic manifestations with a long term overall effect on morbidity and quality of life. Here we review proposed mechanisms underlying the therapeutic effects of immunotherapy for allergic diseases. Further, we discuss both standard and novel approaches and possible future directions in the development of AIT.

Type

Journal article

Journal

NPJ Vaccines

Publisher

Nature

Addresses

Radciffe Department of Medicine, University of Oxford, MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, JR Hospital, Oxford, OX3 9DS, United Kingdom

Keywords

allergy, immunotherapy, vaccine